Prostate cancer early detection

Mark H. Kawachi, Robert R. Bahnson, Michael Barry, Peter R. Carroll, H. Ballentine Carter, William J. Catalona, Jonathan I. Epstein, Ruth B. Etzioni, George P. Hemstreet, Richard J. Howe, Jeff D. Kopin, Paul H. Lange, Hans Lilja, James Mohler, Judd Moul, Robert B. Nadler, Stephan Patterson, Alan Pollack, Joseph C. Presti, Antoinette M. StroupDonald A. Urban, Robert Wake, John T. Wei

Research output: Contribution to journalReview article

26 Scopus citations

Abstract

Since the early 1990s when the ACS developed guidelines for the early detection of prostate cancer, many variants of the tPSA assay have been introduced to increase the sensitivity of screening programs (cancer detection) while maintaining specificity (elimination of unnecessary biopsies). Again, the NCCN guidelines recommend how individuals and their physicians can use these new methods rationally for the early detection of prostate cancer. These guidelines are not designed to provide an argument for using early detection programs for prostate cancer, but are meant to provide a vehicle with which early detection efforts can be practiced in an evidence-based, systematic fashion in patients who choose to participate in these programs.56 These NCCN guidelines incorporate many new validated findings in addition to the DRE and tPSA test. These new factors include percent fPSA, PSAV, cPSA, biopsy pathology, and TRUS-guided biopsy techniques. The panel will re-examine the clinical usefulness of these new modalities annually, and the guidelines will be modified accordingly. In addition, future iterations of these guidelines may incorporate new serum markers currently undergoing clinical investigation. The goal of the NCCN and this guideline panel in updating these algorithms is to help men and clinicians choose a program of early detection of prostate cancer and make decisions about the need for prostate biopsy. Any clinician who uses these guidelines is expected to exercise independent medical judgment in the context of the individual clinical circumstances to determine each patient's need for prostate biopsy. These guidelines will continue to evolve as the field of prostate cancer advances.

Original languageEnglish (US)
Pages (from-to)714-736
Number of pages23
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume5
Issue number7
DOIs
StatePublished - Aug 2007
Externally publishedYes

Keywords

  • Biopsy
  • Carcinoma screening
  • Early detection
  • NCCN Clinical Practice Guidelines
  • Prostate cancer
  • Prostate-specific antigen

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Prostate cancer early detection'. Together they form a unique fingerprint.

  • Cite this

    Kawachi, M. H., Bahnson, R. R., Barry, M., Carroll, P. R., Carter, H. B., Catalona, W. J., Epstein, J. I., Etzioni, R. B., Hemstreet, G. P., Howe, R. J., Kopin, J. D., Lange, P. H., Lilja, H., Mohler, J., Moul, J., Nadler, R. B., Patterson, S., Pollack, A., Presti, J. C., ... Wei, J. T. (2007). Prostate cancer early detection. JNCCN Journal of the National Comprehensive Cancer Network, 5(7), 714-736. https://doi.org/10.6004/jnccn.2007.0064